On January 15, 2026 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, reported the latest update on pancreatic cancer research. Pancreatic cancer remains one of the most lethal human malignancies: median survival after diagnosis is typically measured in months, and the five-year survival rate is below 10 %. Traditional therapies such as surgery, chemotherapy and radiation often fail to achieve durable remission, especially in metastatic or chemoresistant disease. This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma’s pancreatic proenzyme formulation known as PRP.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

What Is PRP and Its Biological Rationale?

Propanc’s lead clinical candidate, PRP, is a proprietary mixture of two pancreatic proenzymes — trypsinogen and chymotrypsinogen — formulated in a synergistic 1:6 ratio and administered intravenously. These proenzymes are hypothesized to target cancer stem cells (CSCs) and modulate malignant cellular programs such as the epithelial to mesenchymal transition (EMT), a process linked to metastasis and drug resistance.

Key Mechanistic Findings from Preclinical Studies include:

Suppression of metastatic processes: PRP reduced angiogenesis (formation of blood vessels that feed tumors) and cell migration in pancreatic cancer models and appeared to reverse EMT markers that contribute to invasiveness.
Enhanced chemosensitivity: Laboratory data suggest PRP makes resistant pancreatic tumor cells more responsive to standard chemotherapies and alters the tumor microenvironment — including reduced fibrosis and dampened TGF-β pathway signaling.
Tumor growth inhibition: In vivo studies in animal models showed significant reduction in pancreatic tumor weight, with >85 % growth inhibition at certain PRP doses versus controls.

Importantly, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PRP in 2017 for the treatment of pancreatic cancer, recognizing the severe unmet need and small patient population.

Clinical Development Status

Propanc has progressed its PRP candidate toward human studies. Following an initial public offering and Nasdaq listing, the company is advancing plans to initiate Phase I/II clinical trials in 2026, starting with dose-finding studies and moving to proof-of-concept studies in pancreatic and other cancers. (MedPath)

Pancreatic Cancer Market: Size and Growth

Pancreatic cancer therapeutics represent a rapidly expanding global market as incidence rises and new treatments emerge. Recent market research provides the following context:

Global Market Projections:

Global pancreatic cancer treatment market: Forecast to grow from ~USD 2.9 billion in 2024 to ~USD 5.8 billion by 2030, representing a CAGR of ~12.3 %. (Grand View Research)
Pancreatic cancer market overall: Some industry projections put the broader pancreatic cancer market (including therapies and diagnostics) from ~$3.25 billion in 2025 to over $10.25 billion by 2034 at ~13.6 % CAGR. (Precedence Research)
Other reports estimate the pancreatic cancer therapeutics and diagnostics market growing toward ~$13.8 billion by 2035 at ~9.9 % CAGR. (Market Research Future)

Propanc’s Market Addressable Opportunity

According to Propanc and external research estimates, the pancreatic cancer segment targeted by PRP is forecast to reach roughly $6.93 billion by 2030.
Combined with ovarian cancer, which is also a focus for PRP, the total addressable market over the coming decade has been cited in the $14 – 18 billion range.
North America — particularly the United States — constitutes one of the largest revenue sectors in this market. (Precedence Research)

Financial Metrics and Propanc’s Position

Propanc Biopharma is a pre-revenue biotechnology company focused on early-stage clinical development:

The company has no product revenues to date and remains development and research oriented. Significant annual net losses have been reported due in large part to non-cash stock-based compensation expenses rather than major R&D outlays. (Reddit)
A recent IPO and Nasdaq listing raised approximately $4 million in gross proceeds, with Propanc positioning itself for clinical advancement of PRP and a recombinant follow-on candidate (Rec-PRP). (Stock Titan)
Despite limited cash flow from operations, the company has entered structural financing arrangements, including a potential $100 million private placement facility to fund further development. (Santé log)

Challenges and Outlook

While the scientific rationale for PRP is compelling, pancreatic cancer remains biologically complex, with historical challenges in translating early preclinical signals to clinical success. Challenges include:

Designing robust clinical trials that show meaningful overall survival benefits.
Demonstrating PRP’s effects on the tumor microenvironment and chemosensitivity translate into improved outcomes for patients.
Navigating competitive therapeutic landscapes with new targeted therapies, immunotherapies, and combination regimens.

Yet, if PRP proves safe and effective, its mechanism of targeting cancer stem cells and modulating EMT could offer a distinct therapeutic option in a market desperate for innovation. Combining that potential with a significant and growing addressable pancreatic cancer market underscores why PRP’s clinical success could have both medical and financial implications in the years ahead.

(Press release, Propanc, JAN 15, 2026, View Source [SID1234662058])

On January 15, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer, reported that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company’s proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"All stakeholders and investors are invited to join the presentation and register for one-on-one meetings to learn more about Phio Pharmaceuticals in our continuing pursuit of innovative pathways towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

Phio’s presentation will begin at 1:45 PM ET on January 22, 2026 and can be accessed live here: WEBCAST LINK FOR PHIO’S PRESENTATION: Webinar Registration – Zoom

Mr. Bitterman will also host one-on-one meetings with investors at the conference, taking place on Wednesday Jan 21, 2026 8:30 AM ET through Thursday Jan 22, 2026 at 5:00 PM ET. Registration is free and you don’t need to be a Sidoti client. REGISTRATION LINK FOR ONE-ON-ONE MEETINGS:  www.sidoti.com/events.

About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")

In 2023, Sidoti & Company, LLC , Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees.  The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti’s coverage universe comprises approximately 160 equities, of which 50 percent participate in the firm’s rapidly growing Company Sponsored Research ("CSR") program.  Events is a leading provider of corporate access through the eight investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Events benefits from Sidoti’s small- and microcap-focused nationwide sales force, which has connections with approximately 2,500 institutional relationships in North America.  This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.

(Press release, Phio Pharmaceuticals, JAN 15, 2026, View Source [SID1234662059])

On January 15, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, reported that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 (a CLDN18.2 antibody-drug conjugate [ADC]), as well as R&D progress on ATG-125 (a B7-H3 x PD-L1 bispecific ADC), its steric hindrance masking AnTenGager T cell engager (TCE) platform, and other key preclinical programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Core Clinical Program: ATG-022

Latest data from the Phase I/II CLINCH study: As of December 25, 2025, among patients with moderate to high CLDN18.2 expression (IHC 2+ > 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 40% (12/30) and the disease control rate (DCR) was 90% (27/30), with a median progression-free survival (mPFS) of 5.09 months and a median overall survival (mOS) of 14.72 months. In the 1.8 mg/kg dose cohort, the ORR was 46.7% (14/30), the DCR was 86.7% (26/30), the mPFS was 6.97 months, and the mOS has not yet been reached. Among patients with low/ultra-low CLDN18.2 expression (IHC 2+ ≤ 20%) treated at the efficacious dose range of 1.8-2.4 mg/kg, the ORR was 28.6% (6/21). In addition, one patient in each of the three dose groups achieved a complete response (CR). These results demonstrated the potent anti-tumor activity of ATG-022 across all levels of CLDN18.2 expression.
Promising frontline combination potential: Compared with the data presented at the Company’s R&D Day in November last year, the 1.8 mg/kg dose group demonstrated a further improvement in ORR and a meaningful prolongation in mPFS, while maintaining a favorable safety profile. The incidence of Grade 3 or higher treatment-related adverse events (TRAEs) was only 19.4%. This differentiated safety profile positions ATG-022 as a potentially best-in-class ADC in terms of safety, with the potential to be combined with checkpoint inhibitors (CPIs) and chemotherapy to transform the current frontline standard-of-care regimen.
First Disclosure of Positive Clinical Signals of ATG-022 in Non-Gastrointestinal Tumors: As of January 6, 2025, among 9 efficacy evaluable patients, the ORR was 22.2% (2/9), and DCR was 88.9% (8/9). These data suggest that ATG-022 may have the potential to treat CLDN18.2-positive non-gastrointestinal tumors, which could expand the treatable patient population beyond gastrointestinal cancers. The efficacy observed to date also supports further exploration of CLDN18.2 as a pan-tumor therapeutic target.
Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and the Phase Ib/II CLINCH-2 study of ATG-022 in Mainland of China and Australia. The Company continues to advance the clinical development of ATG-022 across different lines of gastric cancer treatment, including first-line therapy in combination with checkpoint inhibitors (CPIs) and chemotherapy (CAPOX/FOLFOX); second-line therapy in combination with CPIs; and third-line therapy as monotherapy, covering patients with varying levels of CLDN18.2 expression. In addition, the CLINCH study of ATG-022 includes a basket trial cohort evaluating multiple tumor types, with the majority of patients continuing to receive treatment.
2. Next-Generation ADCs and Proprietary TCEs

ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO+ADC " dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of immuno-oncology (IO) therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive signaling, ATG-125 effectively activates T cells and induces immunological memory. Preclinical studies demonstrate that the bispecific ADC delivers superior in vivo efficacy compared with single-target B7-H3-ADC or PD-L1-ADC approaches. The Company plans to submit an IND for ATG-125 in Q1 2027.

TCE platform with steric hindrance masking technology: AnTenGager is Antengene’s proprietary, second-generation T cell engager (TCE) platform featuring "2+1" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. Leveraging this platform, Antengene has discovered multiple investigational programs:

ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel "2+1" CD19-targeted T-cell engager developed on the AnTenGager TCE platform for the treatment of B cell related autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology (ACR) Annual Meeting showed that in non-human primate (NHP) models, the monkey surrogate of ATG-201 achieved deep and durable depletion of naïve B cells with a favorable safety profile, characterized by only a very mild and transient increase in cytokine levels. The IND-enabling study of ATG-201 has been completed and the IND-submission is under preparation.
ATG-106 (CDH6 x CD3 TCE): A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer. The Company plans to submit an IND for ATG-106 in the first half of 2027.
ATG-112 (ALPPL2 x CD3 TCE): A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumor, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The Company has nominated a preclinical candidate (PCC) in January 2026.
Additional TCE programs for solid tumors: Antengene plans to submit an IND for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer. In addition, ATG-115 (an undisclosed bispecific antibody) and two undisclosed trispecific antibody programs are currently in preclinical development.
3. Innovative Treatment for Autoimmune Diseases: Globally First-in-Class ATG-207

ATG-207 is a globally first-in-class dual-function biologic being developed for the treatment of T cell–mediated autoimmune diseases. The Company plans to present the preclinical data for ATG-207 for the first time at an international scientific conference in 2026.

(Press release, Antengene, JAN 15, 2026, View Source [SID1234662060])

On January 15, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK), reported Dr. Ge Michael, President and CEO was invited to attend the conference and delivered a keynote speech on the morning of January 15 (local time) and presented the Company’s latest achievements in drug R&D, commercialization, and globalization, and outlined its innovation strategy and future development plans at the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA..

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since initiating its innovation journey in 2012, Kelun-Biotech has rapidly emerged as a leader in China’s innovative drug field, building differentiated technology platforms and robust R&D pipelines. Leveraging its global leading OptiDC platform for antibody-drug conjugates (ADCs) and novel drug conjugates (DCs), the Company continuously advances the differentiated development of ADCs and novel DCs, forming a gradient portfolio for treating multiple tumor types. Currently, Kelun-Biotech has two ADC products on market: sacituzumab tirumotecan (sac-TMT, 佳泰莱) and trastuzumab botidotin (舒泰莱), covering breast cancer and lung cancer indications. Additionally, nine uniquely designed ADC and novel DC drugs—including cutting-edge directions such as bispecific ADC and radiopharmaceutical conjugate (RDC) are in clinical stage. For high-incidence tumor types in China, such as breast cancer, lung cancer, and gastrointestinal tumors, the Company has initiated nine pivotal studies, while multiple Phase II clinical studies targeting gynecological tumors are progressing steadily. Furthermore, Kelun-Biotech has also developed several non-DC candidates and expanded indications into non-oncology areas.

Over the past year, Kelun-Biotech has presented multiple research findings at international academic conferences and published in authoritative journals: three were selected for oral presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, and three were selected as Late-Breaking Abstracts (LBA) for oral presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress. Among these, the results of the OptiTROP-Lung04 study of sac-TMT for treating EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) after TKI therapy were presented at the Presidential Symposium session of ESMO (Free ESMO Whitepaper) and simultaneously published in The New England Journal of Medicine, highlighting its global academic and clinical value.

In terms of commercialization, Kelun-Biotech has formed a competitive initial product portfolio. Its core product, the TROP2-directed ADC sac-TMT, has been approved in China for three indications: second-line and above triple-negative breast cancer, second-line and third-line EGFR-mutated NSCLC. The HER2-directed ADC trastuzumab botidotin was approved last year for second-line and above HER2-positive breast cancer, becoming the first domestically developed HER2-directed ADC approved for this indication. Furthermore, the anti-EGFR monoclonal antibody Cetuximab N01 (达泰莱) for RAS wild-type colorectal cancer and the anti-PD-L1 monoclonal antibody tagitanlimab (科泰莱) for nasopharyngeal carcinoma have been launched. Another small-molecule RET inhibitor A400 is expected to be approved within the year, bringing the total number of commercialized products in China to five. Currently, three of the Company’s commercialized products, covering five indications, have been included in the National Reimbursement Drug List (NRDL), further benefiting a broad population of cancer patients.

While strengthening its presence in the domestic market, Kelun-Biotech is actively expanding overseas. It has established collaborations with MSD, Ellipses, Windward Bio and Crescent Biopharma to maximize the value of its pipeline value and corporate worth. Among these, MSD is evaluating 16 global Phase III clinical studies of sac-TMT.

The breakthroughs in both clinical development and commercialization are driven by the Company’s sustained investment in innovative R&D. With over a decade of accumulation in the ADC field, Kelun-Biotech’s proprietary OptiDC platform enables differentiated design of drug candidates, which combines specific targets or targeting mechanisms with the most suitable payload-linker strategy to balance efficacy and safety. Additionally, the company is adopting a "multi-pronged" innovation strategy to continuously enhance platform capabilities. By exploring novel targets, new payloads, and diverse conjugation technologies, it is expanding the application boundaries across both oncology and non-oncology fields.

Looking ahead, Kelun-Biotech will consolidate its foundations in R&D, technologies, platforms, and operations by executing five key development strategies. Concurrently, the Company will elevate its globalization strategy, enhancing its capabilities in product development, registration, and commercialization in ex-China market, advancing on its path to becoming a world-class biopharmaceutical company.

On January 15, 2026 Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, reported it has achieved a major European regulatory milestone for its HT-001 clinical program targeting cancer patients undergoing EGFR inhibitor therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company received a positive regulatory conclusion under the European Union Clinical Trials Information System (CTIS) for Part I. This determination confirms the scientific and regulatory acceptability of the trial design and investigational products. Hoth expects to activate clinical trial sites and initiate the study across multiple European countries.

In parallel, country-specific Part II regulatory decisions in Hungary, Spain, and Poland are expected by January 19, 2026, positioning the program for rapid, multi-national clinical execution.

"This marks a meaningful regulatory inflection point for Hoth and our oncology-focused pipeline," said Robb Knie at Hoth Therapeutics. "Regulators have confirmed the acceptability of our application for this cancer-related indication."

The HT-001 program is being developed to address EGFRI-induced dermatologic toxicities, a common and often dose-limiting complication experienced by cancer patients undergoing treatment. These side effects can negatively impact quality of life, disrupt treatment schedules, and increase overall healthcare burden.

Hoth expects to activate sites, initiate patient enrollment, and advance the program into active clinical execution, representing a critical step toward validating a potential new supportive-care therapy for oncology patients.

(Press release, Hoth Therapeutics, JAN 15, 2026, View Source [SID1234662062])